REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – In 2007-2008, a retrospective analysis of over 9,000 patient records in Germany reported that about one-third of treated MS patients experienced one or more relapses in the preceding year and about 24% were candidates for treatment escalation according to clinical and radiological criteria (Maurer et al. Eur J Neurol 2011;18:1036-1045).

Since that time, the number of options for treatment optimization has expanded considerably, so a second study was performed in the period 2010-2014 (Schmidt et al. ECTRIMS 2015; abstract P294). Read More

REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – The following is a summary of real-world studies of current DMT use in clinical practice. Read More

REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – DECIDE is the second phase III trial evaluating daclizumab, an anti-CD25 monoclonal antibody that modulates IL-2 signalling. Primary results were presented at the American Academy of Neurology annual meeting (Kappos et al. AAN 2015; abstract S4.003) but are not yet published. Subjects (mean age 36 years) were randomized to subcutaneous daclizumab 150 mg q4weeks or intramuscular interferon-beta-1a for 96-144 weeks.

The annualized relapse rate (ARR) was significantly lower with daclizumab versus IFNbeta (0.216 vs. 0.393). The risk of three-month confirmed disability progression was reduced 16% with daclizumab versus active control but did not achieve statistical significance. Read More